Trends in the use and cost of antipsychotics among older adults from 2007 to 2013: a repeated cross-sectional study

Abstract

Background:Recently, several new atypical antipsychotic agents have been introduced in Ontario, and regulatory warnings have been issued regarding use of atypical antipsychotics in older adults. We sought to establish the impact of newer atypical antipsychotics on prescribing rates and costs. Methods:We performed a population-based cross-sectional study of Ontario adults aged 65 years or more using atypical antipsychotics from Jan. 1, 20071, , to Mar. 31, 2013. These people have universal access to publicly funded drugs through the Ontario Health Insurance Plan and the Ontario Drug Benefit. We conducted time-series analysis to assess the impact of the introduction of new atypical antipsychotics on rates of use of atypical antipsychotics and associated expenditures. Results:Rates of atypical antipsychotic use increased following the introduction of new agents in 2009, from 27.6 users per 1000 older adults in the third quarter of 2009 to 29.1 users per 1000 older adults at the end of the study period (p = 0.04). Although prescribing rates for the newer atypical agents (paliperidone, ziprasidone and aripiprazole) remained low relative to their older counterparts (risperidone, olanzapine and quetiapine), rates of aripiprazole use rose to 1.0 user per 1000 older adults by the end of the study period. The proportion of prescriptions that were for brand-name agents fell from 57.5% in the second quarter of 2007 to 6.1% in the second quarter of 2009, and then rose to 11.7% by the end of the study period. By the first quarter of 2013, newer atypical antipsychotic agents were used by 4.4% of atypical antipsychotic users but accounted for 14.1% ($1.2 million of $8.5 million) of atypical antipsychotic expenditures. Interpretation:Although the overall prevalence of use of new atypical antipsychotic agents remains low, their introduction has led to increased prescribing of this class of drugs in older adults. Given the potential cost implications, further study of these trends would be prudent. Abstract ResearchResearch CMAJ OPEN CMAJ OPEN 4(2) E293

Antipsychotic prescription patterns and associated factors among the elderly with psychiatric illnesses

“…The increase in the use of antipsychotics among the elderly seen in this study was in line with the results of previous studies (Rapoport et al, 2005;Foster et al, 2016).…”

Prolonged use of antipsychotic medications in long-term aged care in Australia: a snapshot from the HALT project

“…Adverse drug reactions can persist after cessation of antipsychotic use (Koponen et al, 2017). Although the Therapeutic Goods Administration indication for risperidone (the most commonly used antipsychotic in LTC) specifies a maximum 12-week duration for BPSD (Therapeutic Goods Administration, 2015), reducing prolonged use remains a clinical challenge (Craig et al, 2016;Foster et al, 2016;Maust et al, 2018;Oteri et al, 2016;Sultana et al, 2016;Szczepura et al, 2016;Taipale et al, 2014).…”

No differences in olanzapine‐ and risperidone‐related weight gain between women and men: a meta‐analysis of short‐ and middle‐term treatment

“…Sufficient data were present only for weight changes in case of olanzapine and risperidone. Latest pharmacoepidemiological data report that olanzapine and risperidone are across the three most prescribed AP and, therefore, the presented findings represent a predominant group of patients using AP . Thus, the role of sex has not been explicitly addressed in sufficient detail in a sufficient number of studies hampering definitive conclusions.…”